While a low Vimentin content of CLL cells correlates with an increased survival, the phosphorylation levels of HS1 relate to the clinical course of patients with CLL, with the hyperphosphorylated form of HS1 being associated with a more aggressive disease (Scielzo et al., 2005). Here, VIM is linked to B-cell chronic lymphocytic leukemia.